Currently, there are 256.50M common shares owned by the public and among those 250.87M shares have been available to trade.
The company’s stock has a 5-day price change of 76.41% and 150.03% over the past three months. OCGN shares are trading 65.06% year to date (YTD), with the 12-month market performance down to -13.72% lower. It has a 12-month low price of $0.34 and touched a high of $1.10 over the same period. OCGN has an average intraday trading volume of 2.89 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 69.12%, 81.33%, and 91.75% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Ocugen Inc (NASDAQ: OCGN) shares accounts for 10.25% of the company’s 256.50M shares outstanding.
It has a market capitalization of $243.44M and a beta (3y monthly) value of 3.36. The earnings-per-share (ttm) stands at -$0.32. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.41% over the week and 8.40% over the month.
Analysts forecast that Ocugen Inc (OCGN) will achieve an EPS of $Organon & Co. for the current quarter, $18.71 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Origin Materials, Inc. while analysts give the company a high EPS estimate of $OpGen, Inc.. Comparatively, EPS for the current quarter was $OCEN a year ago. Earnings per share for the fiscal year are expected to increase by 25.44%, and -1.18% over the next financial year.
Looking at the support for the OCGN, a number of firms have released research notes about the stock. Chardan Capital Markets stated their Buy rating for the stock in a research note on March 01, 2023, with the firm’s price target at $3.50.
